News of the Day

The PBS ending a 'topsy turvy' decade as two programs December 16, 2019

The BioPharmaDispatch analysis of the recently released annual PBS Expenditure and Prescriptions report has confirmed the challenge of assessing the scheme based on spending growth but confirms how it has effectively transformed into two programs.

Invites to medicines policy review working group December 10, 2019

Stakeholder groups are expecting to receive invitations this week to participate in the working group to support the development of the scope and terms of reference for the review of the National Medicines Policy.

New leadership for Mundipharma ANZ with Jane Orr announcing retirement December 6, 2019

“The thing that makes Mundipharma such a special company is our people and our culture. I have often commented to friends and colleagues that I have the best job in the industry, and I believe that,” said the retiring managing director.

Department has just handed the industry its argument December 4, 2019

If the industry or individual companies are concerned or even oppose the push to include more information in PBAC Public Summary Documents, the Department of Health has just provided the argument to stop it happening.

Industry pays tribute to policy and advocacy leader December 2, 2019

Past and present industry leaders have paid tribute to one of the leading figures and influencers in its policy and advocacy.

The hunt for 'discussant' presentations November 28, 2019

The publisher of BioPharmaDispatch has lodged a Freedom of Information (FoI) request with the Department of Health seeking documents relating to 'discussant' presentations at November's PBAC meeting.

Australia towards the bottom of drug price index November 26, 2019

Australia has ranked 40 out of 50 countries when it comes to the prices paid for a basket of thirteen commonly prescribed medicines.

Vertex study demonstrates potential power of gene editing November 25, 2019

Vertex and its partner CRISPR Therapeutics have released data from clinical trials showing two patients have potentially been cured of diseases using an emerging gene-editing technique.

The 'zombie' reform that is still meant to happen November 22, 2019

Just in case anyone has forgotten, the full implementation of the reform of the supply chain payment system is budgeted from July next year.

Greg Hunt frustrated over refusal to treat with CAR-T November 21, 2019

Frustration for health minister Greg Hunt with surgeons rebuffing his direct intervention and refusing to use CAR-T cell therapy to treat a patient with stage four non-Hodgkin lymphoma.

December extensions for two cancer medicines November 20, 2019

The listing of MSD's KEYTRUDA (pembrolizumab) will be extended to include its use as a first-line treatment in combination with chemotherapy while Amgen's BLINCYTO (blinatumomab) will be funded for early stage of acute lymphoblastic leukaemia.

Industry better than most but more work required on gender pay gap November 19, 2019

The pharmaceutical industry performs better than others but the gender pay gap remains stubbornly stuck at almost 12.5 per cent.

Latest Video

Most Read

Upjohn's Gareth Richmond on creating the standalone entity

The PBS ending a 'topsy turvy' decade as two programs

Budget update confirms how little is spent on new medicines

These new lists are the 'targets'

Two countries and two major outcomes for the industry

New Stories

Budget update confirms how little is spent on new medicines

Upjohn's Gareth Richmond on creating the standalone entity

The PBS ending a 'topsy turvy' decade as two programs

These new lists are the 'targets'

Two countries and two major outcomes for the industry

Clinical trials: Competition across countries and companies

High in fees low on performance measures

Sign In

Latest Video

Most Read

Upjohn's Gareth Richmond on creating the standalone entity

The PBS ending a 'topsy turvy' decade as two programs

Budget update confirms how little is spent on new medicines

These new lists are the 'targets'

Two countries and two major outcomes for the industry

Follow Us

New Stories

Budget update confirms how little is spent on new medicines

Upjohn's Gareth Richmond on creating the standalone entity

The PBS ending a 'topsy turvy' decade as two programs

These new lists are the 'targets'

Two countries and two major outcomes for the industry

Clinical trials: Competition across countries and companies

High in fees low on performance measures